Aquestive(US:AQST) Globenewswire·2026-01-23 15:14Core Viewpoint - Aquestive Therapeutics, Inc. has faced a significant decline in its stock price due to the FDA identifying deficiencies in its New Drug Application for Anaphylm, raising concerns about the drug's approvability ahead of the upcoming PDUFA action date [5]. Group 1: Company Overview - Aquestive Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with severe allergic reactions [5]. - The company's stock is traded on NASDAQ under the ticker symbol AQST [4]. Group 2: Recent Developments - Shares of Aquestive Therapeutics plunged approximately 40% intraday following the FDA's notification regarding deficiencies in its New Drug Application for Anaphylm [5]. - The FDA's findings currently prevent discussions on labeling and post-marketing requirements, which raises concerns about the application's likelihood of approval [5]. Group 3: Legal Implications - Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics for investors who suffered significant losses due to the recent stock decline [4][5]. - The law firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [4].